natgillin/translations-raw huggingface dataset:
Secondary endpoints included duration of maintenance of a ≥35% reduction from baseline in spleen volume, proportion of patients who had ≥50% reduction in total symptom score, changes in total symptom scores from baseline to week 24, as measured by the modified MF Symptom Assessment Form (MFSAF) v2.0 diary, and overall survival. 
Mjere sekundarnih ishoda uključivali su trajanje održavanja smanjenja ≥35% od početne vrijednosti u volumenu slezene, udio bolesnika koji su imali smanjenje ≥50% u ukupnom zbroju simptoma, promjene u ukupnom zbroju simptoma od početne vrijednosti do 24. tjedna mjereno modificiranim dnevnikom za procjenu simptoma MF-a (engl.
Following a single oral dose of [14C]-labelled ruxolitinib in healthy adult subjects, elimination was predominately through metabolism, with 74% of radioactivity excreted in urine and 22% via faeces. 
C]-označenog ruksolitiniba u zdravih odraslih ispitanika, eliminacija je uglavnom bila putem metabolizma, pri čemu je 74% radioaktivnosti bilo izlučeno u mokraću te 22% putem stolice.
mean values showed little difference between the ruxolitinib-treated and the control-treated MF patients. 
U ispitivanju COMFORT-II srednje vrijednosti pokazale su neznatne razlike između bolesnika s MF-om liječenih ruksolitinibom i onih koji su primali kontrolnu terapiju.
Hypertriglyceridaemia b 
Hipertrigliceridemija b
Constipation a 
Konstipacija a
c grade 4 (<6.5g/dl) 
c stupanj 4 (<6,5 g/dl)
In healthy subjects given ruxolitinib (50 mg single dose) following the potent CYP3A4 inducer rifampicin (600 mg daily dose for 10 days), ruxolitinib AUC was 70% lower than after administration of ruxolitinib alone. 
U zdravih ispitanika koji su uzeli ruksolitinib (jednokratna doza od 50 mg) nakon snažnog CYP3A4 induktora rifampicina (dnevna doza od 600 mg tijekom 10 dana), AUC ruksolitiniba bio je 70% niži nego nakon primjene samog ruksolitiniba.
In the randomised period of the pivotal study in PV patients, one (0.5%) CTCAE grade 3 and no grade 4 urinary tract infection was reported. 
U razdoblju randomizacije ključnog ispitivanja u bolesnika s PV-om prijavljena je jedna (0,5%) infekcija mokraćnog sustava stupnja 3 i niti jedna stupnja 4 prema CTCAE-u.
14 tablets 56 tablets 
14 tableta 56 tableta
The rate of herpes zoster was similar in PV (4.3%) 
Stopa herpes zostera bila je slična u bolesnika s PV-om (4,3%) i u bolesnika s MF-om (4,0%).
- A subject with multiple occurrence of an adverse drug reaction (ADR) is counted only once in that ADR category. 
- Ispitanik u kojeg se više puta pojavi jedna nuspojava na lijek broji se samo jedanput u toj kategoriji nuspojava na lijek.
Secondary endpoints included proportion of patients achieving a ≥35% reduction of spleen volume from baseline at week 24 and duration of maintenance of a ≥35% reduction from baseline spleen volume. 
Mjere sekundarnih ishoda uključivali su udio bolesnika koji su postigli smanjenje u volumenu slezene ≥35% u odnosu na početnu vrijednost do 24. tjedna i trajanje održavanja smanjenja ≥35% od početne vrijednosti volumena slezene.
Long-term safety was evaluated using data from two phase 3 studies including data from patients initially randomised to ruxolitinib (n=184; exposure 0.03 to 43.5 months, median exposure 18.9 months) and patients who received ruxolitinib after crossing over from control treatments (n=149; exposure: 0.2 to 33.5 months, median exposure 12.0 months): With longer exposure, the cumulative frequency of adverse events increased but no new safety findings emerged. 
Dugoročna sigurnost je bila ocjenjivana korištenjem podataka iz dva ispitivanja faze 3 uključujući podatke od bolesnika inicijalno randomiziranih na ruksolitinib (n=184; izloženost 0,03 do 43,5 mjeseci, medijan izloženosti 18,9 mjeseci) i bolesnika koji su primali ruksolitinib nakon prelaska iz kontrolnih skupina liječenja (n=149; izloženost: 0,2 do 33,5 mjeseci, medijan izloženosti 12,0 mjeseci).
Non-melanoma skin cancers (NMSCs), including basal cell, squamous cell, and Merkel cell carcinoma, have been reported in patients treated with ruxolitinib. 
Slučajevi nemelanomskog raka kože, uključujući karcinom bazalnih stanica, skvamoznih stanica i Merkelovih stanica, prijavljeni su u bolesnika liječenih ruksolitinibom.
OUTER CARTON OF MULTIPACK 
VANJSKA KUTIJA VIŠESTRUKOG PAKIRANJA
Other side effects with Jakavi 
Druge nuspojave s Jakavijem
If Jakavi is to be co-administered with strong CYP3A4 inhibitors or dual inhibitors of CYP3A4 and CYP2C9 enzymes (e.g. fluconazole), the unit dose of Jakavi should be reduced by approximately 50%, to be administered twice daily (for monitoring frequency see sections 4.2 and 4.5). 
Ako se Jakavi primjenjuje istodobno sa snažnim CYP3A4 inhibitorima ili dvostrukim inhibitorima enzima CYP3A4 i CYP2C9 (npr. flukonazolom), jediničnu dozu Jakavija treba smanjiti za otprilike 50%, te primjenjivati dvaput dnevno (za učestalost praćenja vidjeti dijelove 4.2 i 4.5).
Headache a 
Glavobolja a
Renal impairment No specific dose adjustment is needed in patients with mild or moderate renal impairment. 
Nije potrebno prilagođavanje doze u bolesnika s blagim do umjerenim oštećenjem bubrega.
The safety and efficacy of these co-administrations are not known (see section 4.5). 
Sigurnost i djelotvornost istodobne primjene nisu poznate (vidjeti dijelove 4.5).
Subsequent doses (single dose of 20 mg or two doses of 10 mg given 12 hours apart in MF patients; single dose of 10 mg or two doses of 5 mg given 12 hours apart in PV patients) should be administered only on haemodialysis days following each dialysis session. 
Naknadne doze (jednokratna doza od 20 mg ili dvije doze od 10 mg dane u razmaku od 12 sati u bolesnika s MF-om; jednokratna doza od 10 mg ili dvije doze od 5 mg dane u razmaku od 12 sati u bolesnika s PV-om) treba primjenjivati samo u dane hemodijalize i to nakon svakog postupka dijalize.
The three most frequent non-haematological adverse reactions were dizziness (9.2%), constipation (8.7%) and hypertension (6.5%). 
Tri najučestalije nehematološke nuspojave bile su omaglica (9,2%), konstipacija (8,7%) i hipertenzija
The primary efficacy endpoint was proportion of patients achieving ≥35% reduction from baseline in spleen volume at week 48 as measured by MRI or CT. 
Mjera primarnog ishoda djelotvornosti bio je udio bolesnika koji su postigli smanjenje ≥35% u odnosu na početnu vrijednost u volumenu slezene u 48. tjednu, mjereno MR-om ili CT-om.
In COMFORT-II, after a median follow-up of 34.7 months, the death rate in patients randomised to ruxolitinib was 19.9% versus 30.1% in patients randomised to best available treatment (BAT); HR 0.48; 95% CI 0.28-0.85; p=0.009. 
U ispitivanju COMFORT-II, nakon medijana praćenja od 34,7 mjeseci, stopa smrtnosti u bolesnika randomiziranih na ruksolitinib bila je 19,9% naspram 30,1% u bolesnika randomiziranih na najbolju dostupnu terapiju (NDT); HR 0,48; 95% CI 0,28-0,85; p=0,009.
Common (may affect up to 1 in 10 people): - fever, cough, difficult or painful breathing, wheezing, pain in chest when breathing (possible symptoms of pneumonia) - frequently passing wind (flatulence) 
Česte (mogu se javiti u manje od 1 na 10 ljudi): - vrućica, kašalj, otežano ili bolno disanje, piskanje, bol u prsnom košu prilikom disanja (mogući simptomi upale pluća) - učestali vjetrovi (nadutost) - zatvor - visoki krvni tlak (hipertenzija), koji također može uzrokovati omaglicu i glavobolje
The concomitant use of cytoreductive therapies and ruxolitinib has not been studied. 
Istodobna primjena citoreduktivnih terapija i ruksolitiniba nije do sada ispitivana.
Time point After 24 weeks 
Nakon 24 tjedna
Haematopoietic growth factors 
Hematopoetski čimbenici rasta
c grade 3 (<1,000 - 500/mm 
c stupanj 3 (<1000 - 500/mm
Jakavi contains lactose. 
Jakavi sadrži laktozu.
c grade 4 (<500/mm 
c stupanj 4 (<500/mm
The maximum dose of ruxolitinib is 25 mg twice daily. 
Najveća dopuštena doza ruksolitiniba je 25 mg dvaput na dan.
There was a 33% reduction in risk of death in the ruxolitinib arm compared to the BAT arm (HR 0.67; 95% CI 0.44-1.02; p=0.062). 
U ruksolitinib skupini opaženo je 33%-tno smanjenje rizika od smrti u odnosu na NDT skupinu (HR 0,67; 95% CI 0,44-1,02; p=0,062).
In COMFORT-I, after a median follow-up of 61.7 months, the death rate in patients randomised to the ruxolitinib arm was 44.5% (69 of 155 patients) versus 53.2% (82 of 154) in patients randomised to placebo. 
U ispitivanju COMFORT-I, nakon medijana praćenja od 61,7 mjeseci, stopa smrtnosti u bolesnika randomiziranih u skupinu koja je primala ruksolitinib bila je 44,5% (69 od 155 bolesnika) naspram 53,2% (82 od 154) u bolesnika randomiziranih na placebo.
Most of the patients with bleeding events during the treatment reported bruising 
Većina bolesnika s događajima krvarenja tijekom liječenja prijavila je modrice (65,3%).
In the randomised period of the pivotal study in PV patients, the mean systolic blood pressure increased by 0.65 mmHg in the ruxolitinib arm versus a decrease of 2 mmHg in the BAT arm. 
U razdoblju randomizacije ključnog ispitivanja u bolesnika s PV-om, srednji sistolički krvni tlak povećao se za 0,65 mmHg u skupini koja je primala ruksolitinib naspram smanjenja od 2 mmHg u skupini koja je primala najbolju dostupnu terapiju.
A single dose of 20 mg or two doses of 10 mg given 12 hours apart is recommended for MF patients with platelet count of >200,000/mm Subsequent doses (single administration or two doses of 10 mg given 12 hours apart) should be administered only on haemodialysis days following each dialysis session. 
Jednokratna doza od 20 mg ili dvije doze od 10 mg dane u razmaku od 12 sati se preporučuju za bolesnike s MF-om s brojem trombocita >200 000/mm Naknadne doze (jednokratna primjena ili dvije doze od 10 mg dane u razmaku od 12 sati) treba primjenjivati samo u dane hemodijalize i to nakon svakog postupka dijalize.
c grade 4 (<25,000/mm 
c stupanj 4 (<25 000/mm
When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily. 
Kada se ruksolitinib primjenjuje sa snažnim CYP3A4 inhibitorima, jediničnu dozu ruksolitiniba treba smanjiti za otprilike 50% te primjenjivati dvaput na dan.
In COMFORT-I, after a median follow-up of 34.3 months, the death rate in patients randomised to the ruxolitinib arm was 27.1% versus 35.1% in patients randomised to placebo; HR 0.687; 95% CI 0.459-1.029; p=0.0668. 
U ispitivanju COMFORT-I, nakon medijana praćenja od 34,3 mjeseca, stopa smrtnosti u bolesnika randomiziranih u skupinu koja je primala ruksolitinib bila je 27,1% naspram 35,1% u bolesnika randomiziranih na placebo; HR 0,687; 95% CI 0,459-1,029; p=0,0668.
Nervous system disorders Dizziness a 
Poremećaji živčanog sustava Omaglica a
In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a dual CYP2C9 and CYP3A4 inhibitor, fluconazole, resulted in ruxolitinib Cmax and AUC that were higher by 47% and 232%, respectively, than with ruxolitinib alone. 
U zdravih ispitanika istodobna primjena ruksolitiniba (jednokratna doza od 10 mg) s dvostrukim CYP2C9 i CYP3A4 inhibitorom, flukonazolom, za posljedicu je imala Cmax i AUC ruksolitiniba koji su bili viši za 47% odnosno 232% nego sa samim ruksolitinibom.
Hepatitis B viral load (HBV-DNA titre) increases, with and without associated elevations in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Jakavi. 
U bolesnika s kroničnim HBV infekcijama koji su primali Jakavi zabilježena su povećanja virusnog opterećenja hepatitisom B (titar HBV-DNK), s povezanim povišenjima alanin aminotransferaze i aspartat aminotransferaze ili bez njih.
Treatment should be discontinued in patients with platelet count less than 50,000/mm or absoute neutrophil count less than 500/mm 
Liječenje treba prekinuti u bolesnika s brojem trombocita manjim od 50 000/mm ili apsolutnim brojem neutrofila manjim od
The recommended starting dose of ruxolitinib in MF is 15 mg twice daily for patients with a platelet count between 100,000/mm and 200,000/mm and 20 mg twice daily for patients with a platelet count of >200,000/mm 3. 
Preporučena početna doza ruksolitiniba za MF je 15 mg dvaput na dan za bolesnike s brojem trombocita između 100 000/mm i 200 000/mm 3, te 20 mg dvaput na dan za bolesnike s brojem trombocita od >200 000/mm 3. Preporučena početna doza ruksolitiniba za PV je 10 mg primijenjeno peroralno dvaput na dan.
Serious bacterial, mycobacterial, fungal, viral and other opportunistic infections have occurred in patients treated with Jakavi. 
Kod bolesnika liječenih Jakavijem javile su se ozbiljne bakterijske, mikobakterijske, gljivične, virusne i druge oportunističke infekcije.
Patients should be carefully monitored with regard to safety and efficacy during ruxolitinib treatment. 
Kod bolesnika tijekom liječenja ruksolitinibom treba pažljivo motriti sigurnost i djelotvornost.
The safety of Jakavi was assessed in 184 patients with PV in two open-label, randomised, controlled studies, the phase 3 RESPONSE study and the phase 3b RESPONSE 2 study. 
Sigurnost Jakavija ocjenjivala se u 184 bolesnika s PV-om u dva otvorena, randomizirana, kontrolirana ispitivanja, ispitivanju faze 3 RESPONSE i ispitivanju faze 3b RESPONSE 2. Nuspojave na lijek navedene u nastavku obuhvaćaju razdoblje randomizacije (do 32. tjedna za RESPONSE i do 28. tjedna za RESPONSE 2) s ekvivalentnom izloženošću ruksolitinibu i najboljoj dostupnoj terapiji (NDT).
In healthy subjects co-administration of ruxolitinib (10 mg single dose) with erythromycin 500 mg twice daily for four days resulted in ruxolitinib Cmax and AUC that were higher by 8% and 27%, respectively, than with ruxolitinib alone. 
U zdravih ispitanika istodobna primjena ruksolitiniba (jednokratna doza od 10 mg) s eritromicinom 500 mg dvaput na dan tijekom četiri dana rezultirala je time da je Cmax ruksolitiniba bio viši za 8%, a AUC za 27% nego sa samim ruksolitinibom.
Excipient with known effect Each tablet contains 285.80 mg lactose monohydrate. 
Svaka tableta sadrži 285,80 mg laktoze hidrat.
Positive (N=121) n (%) 
Pozitivan (N=121) n (%)
Excipient with known effect Each tablet contains 71.45 mg lactose monohydrate. 
Svaka tableta sadrži 71,45 mg laktoze hidrat.
- The recommended starting dose in polycythaemia vera is 10 mg twice daily. 
- Preporučena početna doza kod policitemije vere je 10 mg dvaput na dan.
The recommended starting dose for PV patients with ESRD on haemodialysis is a single dose of 10 mg or two doses of 5 mg given 12 hours apart, to be administered post-dialysis and only on the day of haemodialysis. 
Preporučena početna doza za bolesnike s PV-om i terminalnim bubrežnim zatajenjem koji su na hemodijalizi je jednokratna doza od 10 mg ili dvije doze od 5 mg dane u razmaku od 12 sati, koje treba primijeniti nakon dijalize i to samo na dan hemodijalize.
- Each 20 mg Jakavi tablet contains 20 mg of ruxolitinib. 
- Svaka tableta Jakavi 20 mg sadrži 20 mg ruksolitiniba.
How to store Jakavi 
Kako čuvati Jakavi
Dose adjustment with concomitant strong CYP3A4 inhibitors or fluconazole When ruxolitinib is administered with strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole) the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily (see section 4.5). 
Kada se ruksolitinib primjenjuje sa snažnim CYP3A4 inhibitorima ili dvostrukim inhibitorima enzima CYP2C9 i CYP3A4 (npr. flukonazolom), jediničnu dozu ruksolitiniba treba smanjiti za otprilike 50% te je primjenjivati dvaput na dan (vidjeti dio 4.5).
Excipient with known effect Each tablet contains 142.90 mg lactose monohydrate. 
Svaka tableta sadrži 142,90 mg laktoze hidrat.
Positive (N=110) n (%) 
Pozitivan (N=110) n (%)
The concurrent use of haematopoietic growth factors and ruxolitinib has not been studied. 
Istodobna primjena hematopoetskih čimbenika rasta i ruksolitiniba nije do sada ispitivana.
Positive (N=49) n (%) 
Pozitivan (N=49) n (%)
Jakavi 5 mg tablets Jakavi 10 mg tablets Jakavi 15 mg tablets Jakavi 20 mg tablets 
Jakavi 10 mg tablete Jakavi 15 mg tablete Jakavi 20 mg tablete
Positive (N=113) n (%) 
Pozitivan (N=113) n (%)
Bruising was reported in 10.3% of patients treated with ruxolitinib, 8.1% of patients receiving best available therapy in RESPONSE 
Stvaranje modrica bilo je zabilježeno u 10,3% bolesnika liječenih ruksolitinibom, u 8,1% bolesnika koji su primali najbolju dostupnu terapiju u RESPONSE ispitivanju te u 2,7% bolesnika koji su primali najbolju dostupnu terapiju u RESPONSE 2 ispitivanju.
Jakavi 5 mg tablets Jakavi 10 mg tablets Jakavi 15 mg tablets Jakavi 20 mg tablets ruxolitinib 
Jakavi 10 mg tablete Jakavi 15 mg tablete Jakavi 20 mg tablete ruksolitinib
If you have any questions about how Jakavi works or why this medicine has been prescribed for you, ask your doctor. 
Ako imate ikakvih pitanja o djelovanju Jakavija ili o tome zašto
A dose modification is recommended in patients with severe renal impairment and end-stage renal disease (see section 4.2). 
U bolesnika s teškim oštećenjem bubrega i terminalnim bubrežnim zatajenjem preporučuje se prilagodba doze (vidjeti dio 4.2).
Excipient with known effect Each tablet contains 214.35 mg lactose monohydrate. 
Svaka tableta sadrži 214,35 mg laktoze hidrat.
Jakavi 20 mg tablets 
Jakavi 20 mg tablete
Gastrointestinal disorders Flatulence a 
Flatulencija a
Tell your doctor if you are breast-feeding. 
Obratite se svom liječniku ako dojite.
Negative (N=35) n (%) 
Negativan (N=35) n (%)
Discontinuation of treatment because of thrombocytopenia occurred in 0.7% of patients receiving ruxolitinib and 0.9% 
Do prekida liječenja zbog trombocitopenije došlo je kod 0,7% bolesnika koji su primali ruksolitinib te kod 0,9% bolesnika koji su primali kontrolne režime.
- Each 5 mg Jakavi tablet contains 5 mg of ruxolitinib. 
- Svaka tableta Jakavi 5 mg sadrži 5 mg ruksolitiniba.
- Each 15 mg Jakavi tablet contains 15 mg of ruxolitinib. 
- Svaka tableta Jakavi 15 mg sadrži 15 mg ruksolitiniba.
Other bleeding events (including events such as epistaxis, post-procedural haemorrhage, gingival bleeding) were reported in 8.7% of patients treated with ruxolitinib, 6.3% of patients treated with best available therapy in RESPONSE study and 6.7% of patients treated with best available therapy in RESPONSE 2 study. 
U jednog bolesnika liječenog ruksolitinibom došlo je do događaja krvarenja stupnja 3 (postproceduralno krvarenje); nije zabilježeno nijedno krvarenje stupnja 4. Drugi događaji krvarenja (uključujući događaje kao što su epistaksa, postproceduralno krvarenje, gingivalno krvarenje) bili su zabilježeni u 8,7% bolesnika liječenih ruksolitinibom, u 6,3% bolesnika liječenih najboljom dostupnom terapijom u RESPONSE ispitivanju te u 6,7% bolesnika koji su primali najbolju dostupnu terapiju u RESPONSE 2 ispitivanju.
Jakavi 10 mg tablets EU/1/12/773/014-016 
Jakavi 10 mg tablete EU/1/12/773/014-016
Jakavi 20 mg tablets EU/1/12/773/010-012 
Jakavi 20 mg tablete EU/1/12/773/010-012
Jakavi 5 mg tablets EU/1/12/773/004-006 
Jakavi 5 mg tablete EU/1/12/773/004-006
Jakavi 15 mg tablets EU/1/12/773/007-009 
Jakavi 15 mg tablete EU/1/12/773/007-009
Negative (N=27) n (%) 
Negativan (N=27) n (%)
Negative (N=20) n (%) 
Negativan (N=20) n (%)
Negative (N=40) n (%) 
Negativan (N=40) n (%)
Jakavi 10 mg tablets 
Jakavi 10 mg tablete
Jakavi 20 mg tablets are white to almost white elongated tablets with “NVR” debossed on one side and “L20” debossed on the other side. 
Jakavi 20 mg tablete su bijele do gotovo bijele duguljaste tablete s oznakom „NVR“ utisnutom na jednoj strani i oznakom „L20“ utisnutom na drugoj strani.
was 0-2 mmHg on ruxolitinib versus a decrease of 2-5 mmHg in the placebo arm. 
U ispitivanju COMFORT-I (bolesnici s MF-om) srednje povišenje sistoličkog krvnog tlaka od početnog bilo je 0-2 mmHg na terapiji ruksolitinibom u usporedbi sa smanjenjem od 2-5 mmHg u kraku koji je primao placebo.
Jakavi 15 mg tablets 
Jakavi 15 mg tablete
Strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole) In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a strong CYP3A4 inhibitor, ketoconazole, resulted in ruxolitinib Cmax and AUC that were higher by 33% and 91%, respectively, than with ruxolitinib alone. 
Snažni CYP3A4 inhibitori (kao što su, između ostalih, boceprevir, klaritromicin, indinavir, itrakonazol, ketokonazol, lopinavir/ritonavir, ritonavir, mibefradil, nefazodon, nelfinavir, posakonazol, sakvinavir, telaprevir, telitromicin, vorikonazol)
Jakavi 5 mg tablets 
Jakavi 5 mg tablete
- Each 10 mg Jakavi tablet contains 10 mg of ruxolitinib. 
Jakavi 10 mg sadrži 10 mg ruksolitiniba.
Cellulose, microcrystalline Magnesium stearate Silica, colloidal anhydrous Sodium starch glycolate (Type A) Povidone K30 
6.1 Popis pomoćnih tvari celuloza, mikrokristalična magnezijev stearat silicijev dioksid, koloidni, bezvodni natrijev škroboglikolat, vrste A povidon K30 hidroksipropilceluloza 300 do 600 cps laktoza hidrat
Round curved white to almost white tablets of approximately 9.3 mm in diameter with “NVR” debossed on one side and “L10” debossed on the other side. 
Okrugle, zaobljene, bijele do gotovo bijele tablete promjera približno 9,3 mm, s oznakom „NVR“ utisnutom na jednoj strani i oznakom „L10“ utisnutom na drugoj strani.
Elongated curved white to almost white tablets of approximately 16.5 x 7.4 mm with “NVR” debossed one one side and “L20” debossed on the other side. 
Izdužene, zaobljene, bijele do gotovo bijele tablete veličine približno 16,5 x 7,4 mm, s oznakom „NVR“ utisnutom na jednoj strani i oznakom „L20“ utisnutom na drugoj strani.
Jakavi 15 mg tablets are white to almost white oval tablets with “NVR” debossed on one side and “L15” debossed on the other side. 
Jakavi 15 mg tablete su bijele do gotovo bijele ovalne tablete s oznakom „NVR“ utisnutom na jednoj strani i „L15“ utisnutom na drugoj strani.
Jakavi 20 mg tablets ruxolitinib 
Jakavi 20 mg tablete ruksolitinib
Ovaloid curved white to almost white tablets of approximately 15.0 x 7.0 mm with “NVR” debossed on one side and “L15” debossed on the other side. 
Ovalne, zaobljene, bijele do gotovo bijele tablete veličine približno 15,0 x 7,0 mm, s oznakom „NVR“ utisnutom na jednoj strani i oznakom „L15“ utisnutom na drugoj strani.
A complete blood cell count, including a white blood cell count differential, must be performed before initiating therapy with Jakavi. 
Prije početka liječenja Jakavijem mora se napraviti kompletna krvna slika, uključujući i diferencijalnu krvnu sliku leukocita.
Round curved white to almost white tablets of approximately 7.5 mm in diameter with “NVR” debossed on one side and “L5” debossed on the other side. 
Okrugle, zaobljene, bijele do gotovo bijele tablete promjera približno 7,5 mm, s oznakom „NVR“ utisnutom na jednoj strani i oznakom „L5“ utisnutom na drugoj strani.
Jakavi 10 mg tablets are white to almost white round tablets with “NVR” debossed on one side and “L10” debossed on the other side. 
Jakavi 10 mg tablete su bijele do gotovo bijele okrugle tablete s oznakom „NVR“ utisnutom na jednoj strani i oznakom „L10“ utisnutom na drugoj strani.
Each tablet contains 20 mg ruxolitinib (as phosphate). 
Svaka tableta sadrži 20 mg ruksolitiniba (u obliku ruksolitinibfosfata).
Vascular disorders Hypertensiona 
Krvožilni poremećaji Hipertenzija a
Jakavi 10 mg tablets ruxolitinib 
Jakavi 10 mg tablete ruksolitinib
Follow all the doctor's instructions carefully. 
Što morate znati prije nego počnete uzimati Jakavi Pažljivo slijedite sve liječničke upute.
Common 
Kod
Jakavi 5 mg tablets ruxolitinib 
Jakavi 5 mg tablete ruksolitinib
Each tablet contains 15 mg ruxolitinib (as phosphate). 
Svaka tableta sadrži 15 mg ruksolitiniba (u obliku ruksolitinibfosfata).
The frequency of grade 3-4 events was similar for patients treated with ruxolitinib or reference treatments 
Učestalost događaja stupnja 3-4 bila je slična za bolesnike liječene ruksolitinibom ili referentnim terapijama (4,7% u odnosu na 3,1%).
Each tablet contains 5 mg ruxolitinib (as phosphate). 
Svaka tableta sadrži 5 mg ruksolitiniba (u obliku ruksolitinibfosfata).